title: Lymphocyte subsets and inflammatory mediators in patients with subacute sclerosing panencephalitis.
abstract: A defective cell-mediated immunity and inflammatory cytokines are suggested in the pathogenesis of subacute sclerosing panencephalitis. In this study we analyzed lymphocyte subsets in peripheral blood and concentrations of interleukin-1alpha (IL-1alpha), interleukin-2 (IL-2alpha), tumor necrosis factor-alpha (TNF-alpha), and platelet activating factor in plasma and cerebrospinal fluid before and after immunomodulatory therapy (interferon-alpha plus isoprinosine) in three patients with subacute sclerosing panencephalitis. Increased percentage of CD8+cells (T-suppressor/cytotoxic cell) and CD16+CD56+cells (NK cell) and reduced percentage of CD3+/HLA-DR+ (active T-cell) and CD3+ (total T-cell) cells were found before therapy. After immunomodulatory therapy, CD3+/HLA-DR+ (active T-cell) cells were markedly increased and there was a slight increase in the percentages of all lymphocyte subsets in the patients. The concentrations of platelet activating factor in plasma and cerebrospinal fluid were higher than the mean value in controls. Cerebrospinal fluid and plasma TNF-alpha and IL-2 levels were nondetectable in two patients who had a stationary course of disease and were markedly elevated in patient 3, who displayed a rapidly progressive course.
authors.affiliation: Department of Pediatric Neurology, Ege University Faculty of Medicine, Izmir, Turkey. htekgul@med.ege.edu.tr
authors.forename: H
authors.initials: H
authors.lastname: Tekgül
authors.forename: S
authors.initials: S
authors.lastname: Tutuncuoglu
authors.forename: N
authors.initials: N
authors.lastname: Kutukçuler
authors.forename: G
authors.initials: G
authors.lastname: Dizdarer
authors.forename: A
authors.initials: A
authors.lastname: Huseyinov
mesh_terms: D000276:Adjuvants, Immunologic / Q000627:therapeutic use; D000293:Adolescent; D000998:Antiviral Agents / Q000627:therapeutic use; D002675:Child, Preschool; D005260:Female; D006801:Humans; D018836:Inflammation Mediators / Q000097:blood / Q000134:cerebrospinal fluid / Q000378:metabolism*; D007542:Inosine Pranobex / Q000627:therapeutic use; D016898:Interferon-alpha / Q000627:therapeutic use; D007375:Interleukin-1 / Q000378:metabolism; D007376:Interleukin-2 / Q000378:metabolism; D016131:Lymphocyte Subsets / Q000187:drug effects / Q000378:metabolism*; D008297:Male; D010972:Platelet Activating Factor / Q000378:metabolism; D013344:Subacute Sclerosing Panencephalitis / Q000134:cerebrospinal fluid / Q000188:drug therapy* / Q000276:immunology*; D014409:Tumor Necrosis Factor-alpha / Q000378:metabolism
chemical_list: D000276:Adjuvants, Immunologic; D000998:Antiviral Agents; D018836:Inflammation Mediators; D016898:Interferon-alpha; D007375:Interleukin-1; D007376:Interleukin-2; D010972:Platelet Activating Factor; D014409:Tumor Necrosis Factor-alpha; D007542:Inosine Pranobex